Full Text View
Tabular View
No Study Results Posted
Related Studies
DOXIL® vs. Xeloda® as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older
This study has been terminated.
( The study was terminated due to poor accrual after enrolling 62 of planned 300 patients in 20 months. )
Study NCT00082095   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: April 29, 2004   Last Updated: April 11, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Cancer of Breast
Breast Cancer
Cancer of the Breast
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Additional drug interventions recognized in this trial
Capecitabine
Doxorubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services